Skip to main content
IRD
NASDAQ Life Sciences

Opus Genetics Secures Initial $35M Funding from Senior Secured Note Agreement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.23
Mkt Cap
$373.435M
52W Low
$0.731
52W High
$5.81
52W Position info
616% above low
Off High info
10.0% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

IRD has more than doubled off its 52-week low of $0.731.

Summary

Opus Genetics, Inc. announced the funding of an initial $35 million tranche from its previously disclosed senior secured note purchase agreement, providing significant capital for operations.


Key Events · Financing and Capital Events · IRD

  • Initial Debt Funding Secured

    Opus Genetics received $35 million in funding on April 21, 2026, as the initial tranche of its senior secured note purchase agreement.

  • Total Committed Capital

    The company has a commitment for up to $105 million in senior secured notes, with an additional $50 million uncommitted, from the agreement dated April 2, 2026.

  • Note Terms

    The initial notes mature on April 21, 2033, bear floating interest, and are secured by substantially all of the company's assets.


Analysis · IRD · Life Sciences

This 8-K reports the critical step of funding the initial $35 million tranche of a senior secured note agreement, which was previously announced on April 2, 2026. For a life sciences company like Opus Genetics, securing this substantial debt financing is a positive development as it significantly extends the company's cash runway and supports ongoing clinical development without immediate equity dilution. The total committed amount is $105 million, with an additional $50 million uncommitted, indicating further potential capital access. Investors should monitor the company's use of these funds and progress on its clinical pipeline.

How filings like this one have moved

In the 30 days to Sep 12, 2026, 35.3% of the 1492 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IRD was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.4M. The 52-week trading range was $0.73 to $5.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IRD - Latest Insights

IRD
Sep 09, 2026, 10:48 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $5.52
Real-time Price: $5.95 info
Change: +$0.4339 (+8%) info
Market Cap: $502.503M info
IRD
Sep 09, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $5.95 info
Change: +$1.38 (+30%) info
Market Cap: $502.503M info
IRD
Sep 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.64
Real-time Price: $5.95 info
Change: +$1.31 (+28%) info
Market Cap: $502.503M info
IRD
Aug 06, 2026, 8:24 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $5.95 info
Change: +$2.04 (+52%) info
Market Cap: $502.503M info
IRD
Aug 06, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.75
Real-time Price: $5.95 info
Change: +$2.20 (+59%) info
Market Cap: $502.503M info